Bryn Mawr Trust Advisors LLC Increases Stake in Medtronic PLC $MDT

Bryn Mawr Trust Advisors LLC raised its stake in shares of Medtronic PLC (NYSE:MDT) by 8.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 141,126 shares of the medical technology company’s stock after purchasing an additional 11,200 shares during the quarter. Bryn Mawr Trust Advisors LLC’s holdings in Medtronic were worth $12,302,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. 1248 Management LLC purchased a new position in Medtronic in the 1st quarter worth $26,000. Twin Tree Management LP acquired a new position in shares of Medtronic in the first quarter valued at about $29,000. Activest Wealth Management increased its holdings in shares of Medtronic by 3,577.8% in the first quarter. Activest Wealth Management now owns 331 shares of the medical technology company’s stock valued at $30,000 after purchasing an additional 322 shares during the period. Hughes Financial Services LLC purchased a new position in shares of Medtronic in the first quarter worth about $32,000. Finally, Investment Management Corp VA ADV lifted its holdings in shares of Medtronic by 144.2% during the first quarter. Investment Management Corp VA ADV now owns 403 shares of the medical technology company’s stock worth $36,000 after purchasing an additional 238 shares during the period. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Medtronic Trading Down 0.3%

Shares of Medtronic stock opened at $90.10 on Friday. The firm has a 50-day simple moving average of $94.21 and a two-hundred day simple moving average of $89.88. The company has a market cap of $115.57 billion, a P/E ratio of 24.82, a price-to-earnings-growth ratio of 2.42 and a beta of 0.77. Medtronic PLC has a fifty-two week low of $79.29 and a fifty-two week high of $99.37. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.50 and a current ratio of 2.01.

Medtronic (NYSE:MDT) last announced its quarterly earnings results on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share for the quarter, beating the consensus estimate of $1.23 by $0.03. The firm had revenue of $8.58 billion during the quarter, compared to analyst estimates of $8.37 billion. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.Medtronic’s revenue for the quarter was up 7.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.23 EPS. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. As a group, equities analysts predict that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, October 17th. Shareholders of record on Friday, September 26th were paid a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a yield of 3.2%. The ex-dividend date was Friday, September 26th. Medtronic’s payout ratio is 78.24%.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on MDT shares. Weiss Ratings reissued a “buy (b-)” rating on shares of Medtronic in a research report on Wednesday, October 8th. William Blair upgraded shares of Medtronic to a “hold” rating in a research note on Friday, July 11th. Robert W. Baird boosted their target price on shares of Medtronic from $94.00 to $96.00 and gave the company a “neutral” rating in a research report on Wednesday, August 20th. Truist Financial increased their price target on Medtronic from $96.00 to $103.00 and gave the stock a “hold” rating in a research report on Wednesday, October 15th. Finally, BTIG Research reiterated a “neutral” rating on shares of Medtronic in a research note on Friday, July 11th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $102.82.

Insider Activity at Medtronic

In other Medtronic news, Director William R. Jellison bought 2,500 shares of Medtronic stock in a transaction dated Monday, August 25th. The stock was acquired at an average cost of $92.37 per share, for a total transaction of $230,925.00. Following the completion of the transaction, the director directly owned 5,000 shares of the company’s stock, valued at approximately $461,850. This represents a 100.00% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Harry Skip Kiil sold 8,605 shares of the business’s stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total value of $788,045.90. Following the transaction, the executive vice president directly owned 35,615 shares in the company, valued at $3,261,621.70. This trade represents a 19.46% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.26% of the stock is currently owned by insiders.

Medtronic Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.